Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14864491 | 0.94 | RAB9A (0.48) | RAB9AMAPTSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL8363106 | 0.91 | RAB9A (0.50) | RAB9AMAPTACHETDP1SMN1; SMN2 | |
| SCHEMBL9451018 | 0.88 | MEN1 (0.41) | RAB9AMAPTSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL9778697 | 0.84 | KDM4E (0.44) | RAB9ASMN1; SMN2ALDH1A1LMNAKMT2A | |
| SCHEMBL9778775 | 0.80 | HRH3 (0.50) | RAB9AMAPTACHESMN1; SMN2ALDH1A1 | |
| SCHEMBL17818427 | 0.79 | SLC18A3 (0.40) | RAB9AMAPTSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL9778800 | 0.78 | KCNH2 (0.44) | SMN1; SMN2ALDH1A1KMT2AMEN1 | |
| SCHEMBL13337975 | 0.78 | SMN1; SMN2 (0.37) | RAB9AMAPTSMN1; SMN2LMNAKMT2A | |
| SCHEMBL2633867 | 0.77 | MAPK1 (0.47) | ALDH1A1LMNASLC18A3KMT2AMAPK1 | |
| SCHEMBL13262184 | 0.77 | HPGD (0.34) | RAB9ASMN1; SMN2ALDH1A1LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0137968-B1 | PROCESS FOR THE PREPARATION OF 1-ARYLPROPANE-1,3-DIOL DIACYLATES | HÜLS AKTIENGESELLSCHAFT (DE) | 1988-03-09 | — | — | EP | claimed |
| US-9309463-B2 | Liquid crystal compound, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2016-04-12 | — | — | US | disclosed |
| US-8956552-B2 | Cyclohexene-3,6-diyl compound, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2015-02-17 | — | — | US | disclosed |
| US-8846164-B2 | Compound having propyl ether as bonding group, liquid crystal composition thereof and liquid crystal display device thereof | JNC CORPORATION (JP) | 2014-09-30 | — | — | US | disclosed |
| US-20140077131-A1 | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2014-03-20 | — | — | US | disclosed |
| US-20130277612-A1 | CYCLOHEXENE-3,6-DIYL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION | 2013-10-24 | — | — | US | disclosed |
| US-20130253008-A1 | SUBSTITUTED AZOLES, ANTIVIRAL ACTIVE COMPONENT, PHARMACEUTICAL COMPOSITION, METHOD FOR PREPARATION AND USE THEREOF | ALLA CHEM LLC (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130126783-A1 | COMPOUND HAVING PROPYL ETHER AS BONDING GROUP, LIQUID CRYSTAL COMPOSITION THEREOF AND LIQUID CRYSTAL DISPLAY DEVICE THEREOF | JNC PETROCHEMICAL CORPORATION (JP) | 2013-05-23 | — | — | US | disclosed |
| US-20120168677-A1 | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2012-07-05 | — | — | US | disclosed |
| US-7790715-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-09-07 | — | — | US | disclosed |
| US-20100117030-A1 | Monocapped conductive polymers with alkenyl or alkynyl end groups and block copolymers therefrom | CARNEGIE MELLON UNIVERSITY | 2010-05-13 | — | — | US | disclosed |
| US-20070010511-A1 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2007-01-11 | — | — | US | disclosed |
| US-5744676-A | DIMERIZATION, CATALYSTS | AMOCO CORPORATION | 1998-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120168677-A1 | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | CXCR1, OCIAD1, LEO1 | RAB9A 1106/4885MAPT 1566/4885ACHE 4704/4885 |
| US-20070010511-A1 | Organic compounds | REN, ACE, ACE2 | RAB9A 1066/4885MAPT 2397/4885ACHE 403/4885 |
| US-20130253008-A1 | SUBSTITUTED AZOLES, ANTIVIRAL ACTIVE COMPONENT, PHARMACEUTICAL COMPOSITION, METHOD FOR PREPARATION AND USE THEREOF | HCCS, EIF2AK2, HAVCR2 | RAB9A 4117/4885MAPT 4737/4885ACHE 4289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.